Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2006

View Archived Issues

Novel anti-Trx-1 reductase prodrugs demonstrate antitumor activity

Preclinical profile of promising clinical candidate ACP-103

No serious side effects in ongoing phase II study of NX-1207

FDA review of Keflex sNDA ongoing

Spectrum closes acquisition of Targent oncology assets

Boston Scientific completes combination with Guidant

New phase IIIb extension trial for Acapodene

NDA submission planned for room-temperature formulation of MNTX

Astellas closes CNS research in Edinburgh

FAST I phase III trial of icatibant for HAE completes randomization

BioVant shows potential as adjuvant for avian flu vaccine

U.S. study of NOV-205 for hepatitis C cleared to begin

Stem cell therapy product PLX-1 investigated in new preclinical study

FDA extends review for Sparlon in ADHD

Alcon and Amgen collaborate on therapeutics for eye diseases

Neuropharma advances NP-031112 for Alzheimer's disease into clinic

Fesoterodine superior to tolterodine in overactive bladder trial

Urinary incontinence improved by cizolirtine in overactive bladder patients

Pfizer announces new tolterodine study and releases data on overactive bladder prevalence

CYT005-AllQbG10 shows long-term efficacy in house dust mite allergy patients

TG-4001 enables avoidance of surgery in CIN2/3 patients

Amitiza now available for chronic idiopathic constipation

Novel treatment options for autoimmune disorders described in recent patent literature

Recent patents report new treatments for gastrointestinal disorders

New androgen receptor antagonists emerge from Pfizer R&D

PharmaMar presents preclinical data on its new Kahalalide F derivative

Arius Research presents data on their new anticancer antibodies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.